Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 16/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 16/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6510331 | 0.99 | ITGA4 (0.57) | ITGA4ITGB1ITGB7LNPEPITGB3 | |
| SCHEMBL295783 | 0.88 | ITGB1 (0.53) | ITGA4ITGB1ITGB7LNPEPITGA5 | |
| SCHEMBL1240417 | 0.88 | ITGB1 (0.53) | ITGA4ITGB1ITGB7LNPEPITGA5 | |
| Hydrochloric Acid SCHEMBL7391192 | 0.87 | ITGB1 (0.52) | ITGA4ITGB1ITGB7LNPEPITGA5 | |
| SCHEMBL7428248 | 0.86 | ITGA4 (0.76) | ITGA4ITGB1ITGB7ITGB3ITGAV | |
| SCHEMBL7424019 | 0.82 | LNPEP (0.41) | ITGA4ITGB1LNPEPATM | |
| SCHEMBL27542813 | 0.81 | ITGB1 (0.60) | ITGA4ITGB1ITGB7LNPEP | |
| SCHEMBL6639882 | 0.81 | ITGB1 (0.60) | ITGA4ITGB1ITGB7LNPEP | |
| SCHEMBL6515360 | 0.81 | ITGB1 (0.67) | ITGA4ITGB1 | |
| SCHEMBL28742827 | 0.80 | ITGB1 (0.46) | ITGA4ITGB1ITGB7LNPEPITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | CELLTECH THERAPEUTIS, LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-1051399-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037618-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | PAH, VCAM1, IL4I1 | ITGA4 5/4885ITGB1 8/4885ITGB7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.